Cargando…
Phage therapy for secondary bacterial infections with COVID-19
With more than 200 million people affected and 4.5 million deaths so far, the coronavirus disease 2019 (COVID-19) pandemic has become one of the greatest disasters in human history. Secondary bacterial infections (SBIs) are a known complication of viral respiratory infections, and are significantly...
Autores principales: | Wu, Nannan, Chen, Li-Kuang, Zhu, Tongyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576063/ https://www.ncbi.nlm.nih.gov/pubmed/34800893 http://dx.doi.org/10.1016/j.coviro.2021.11.001 |
Ejemplares similares
-
Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients
por: Wu, Nannan, et al.
Publicado: (2021) -
Regulations of phage therapy across the world
por: Yang, Qimao, et al.
Publicado: (2023) -
Phage-Derived Depolymerase: Its Possible Role for Secondary Bacterial Infections in COVID-19 Patients
por: Nazir, Amina, et al.
Publicado: (2023) -
Characterization of Phage Resistance and Their Impacts on Bacterial Fitness in Pseudomonas aeruginosa
por: Li, Na, et al.
Publicado: (2022) -
The Future of Phage: Ethical Challenges of Using Phage Therapy to Treat Bacterial Infections
por: Anomaly, Jonathan
Publicado: (2020)